Since accumulation of mutant AAT at hepatic sites is considered a primary mechanism for proteotoxicity associated with AATD, several strategies have been attempted to inhibit aggregation of mutant AAT molecules [13,14,15,17,18,20]. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.